Bolt Biotherapeutics, Inc.
Annual report (10-K)
Latest 10-K filed Mar 12, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Bolt Biotherapeutics, Inc.
| Name | Roles | Filings |
|---|---|---|
| Lee Frank D. | Director | 4 |
| Perez Edith A. | Officer | 4 |
| Shah Mahendra | Director | 4 |
| Miller Richard A MD | Director | 3 |
| Schatzman Randall C | OfficerDirector | 3 |
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Bolt Biotherapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Engleman Edgar | 12 | 0% | -28.0% | -29.3% | -15.8% | -39.5% |
| 2 | Vivo Capital Fund VIII, L.P. | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 3 | Vivo Capital Surplus Fund VIII, L.P. | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 4 | Vivo Capital VIII, LLC | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 5 | Vivo Opportunity Fund Holdings, L.P. | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 6 | Vivo Opportunity, LLC | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 7 | Vivo Panda Fund, L.P. | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 8 | Vivo Panda, LLC | 12 | 0% | -23.5% | -22.6% | -15.8% | -32.9% |
| 9 | Nemec Sarah | 4 | 0% | -19.4% | -20.3% | -12.0% | -25.1% |
| 10 | Quinn William P. | 7 | 29% | -6.7% | -19.7% | +33.7% | -31.5% |
All filings
79 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|